Inflazome
Targeting inflammation at its source.
Dublin, Ireland · Founded 2016 · $63.0M raised
- Headquarters
- Dublin
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- inflazome.com
- Total Funding
- $63.0M
- Last Round
- $63.0M Series BNov 2018
- Rounds
- 1
About
Inflazome was a Dublin-based biotech company developing orally available small molecule NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases including Parkinson's, Alzheimer's, arthritis, and cardiovascular conditions. Founded in 2016 by Prof. Matt Cooper and Prof. Luke O'Neill, the company advanced two clinical-stage drugs before being acquired by Roche for €380 million in 2020.
Summary
Inflazome is a Biotech company based in Dublin, Ireland, founded in 2016. It has raised $63.0M in total across 1 round, most recently a $63.0M Series B round in Nov 2018.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2018
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...